Merck & Co. announced a third consecutive phase 3 study win for its oral PCSK9 inhibitor, advancing its CORALreef program for hyperlipidemia treatment. With positive clinical results in broader patient populations, Merck is strategically moving towards regulatory interactions to secure approval. The program aims to address cardiovascular risk by targeting PCSK9 pathways, potentially offering oral alternatives to existing injectable therapies.